

May 27, 2020



Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference

AUSTIN, May 27, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that President and Chief Executive Officer, Cameron Reynolds has been invited to present at **The Role of Cell Therapy and Clarity on Testing** Conference organised by the Maxim Group.

Event Details: Wednesday, May 27, 10am-2pm U.S. Eastern Time

10am Introduction

10:15am Panel Session: Cell therapy for ARDS - When Remdesivir is not enough

12pm Panel Session: Testing & Susceptibility - Clearing the Air (Volition presenting)

About Maxim's Virtual Conference

This iteration of Maxim's ongoing M-Vest Infectious Disease Virtual Conference Series focuses in on two key areas related to the ongoing pandemic; cell-based therapies and testing. Please contact Soraya Dorce (sdorce@maximgrp.com) or visit [M-Vest](#) for more information and to register for the conference.

The Science Behind Nu.Q™ and COVID-19

White blood cells help protect the body against infection. White cells engulf invading viruses and bacteria and produce antibodies against them. In addition, white cells also eject chromatin material out of the cell to form NETs which catch and trap invading viruses. In a respiratory infection, white cells migrate to the lungs to protect them from the virus. However, SARS and pneumonia are associated with an inappropriate hyperimmune response to the virus involving massive ejection of NETs into the blood by white blood cells which is highly damaging to the lungs. The ejected NETs material is made up of nucleosomes which can be detected in minute quantities using Volition's Nu.Q™ nucleosome assays. Volition is now testing this clinically to determine whether elevated NETs levels in the blood are predictive of complications arising from viral infection such as COVID-19.

- A proof of concept study involving 34 polymerase chain reaction (PCR) COVID-19 positive subjects and 50 control subjects revealed that nucleosomes were highly elevated in the PCR positive subjects.
- Preliminary study results demonstrated an Area Under the Curve (AUC) for a single Nu.Q™ assay of 98.7% for PCR positive COVID versus control subjects with a

sensitivity of 100% at 94% specificity.

- A second Nu.Q™ assay also showed promising results with an AUC of 86.2%.
- Volition plans to utilise results of this trial and other ongoing studies to further its aim of developing a clinically useful product to help in the battle against the COVID-19 global pandemic and potentially other diseases.

Volition has not yet successfully developed a triage test for COVID-19 and is in investigational stages only.

About Volition

Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.

For more information about Volition, visit Volition's website volition.com or connect with us via:

Twitter: <https://twitter.com/volitionrx>

LinkedIn: <https://www.linkedin.com/company/volitionrx>

Facebook: <https://www.facebook.com/VolitionRx/>

YouTube: <https://www.youtube.com/user/VolitionRx>

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Batchelor, Volition mediarelations@volition.com +44 (0)7557 774620	Scott Powell, Volition investorrelations@volition.com +1 (646) 650 1351
Jen Lewis, Pegasus jen.lewis@thisispegasus.co.uk +44 (0)7809 867943	Joseph Green, Edison Advisors jgreen@edisongroup.com +1 (646) 653 7030

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans,"

"aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the timing of the results from the preliminary trial with the University Hospital of Liège, Belgium and additional trials, the effectiveness of Volition's blood-based diagnostic tests in predicting the progression of complications in COVID-19 patients, as well as Volition's ability to develop and successfully commercialize such test platforms for accurate stratification of COVID-19 patients. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties including, without limitation, results of studies testing the efficacy of its COVID-19 triage test; regulatory clearances or approvals necessary prior to commercialization of its COVID-19 triage test; ; marketplace acceptance of its COVID-19 triage test; and its ability to secure adequate intellectual property protection. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Additional risks include, among others, Volition's failure to develop and commercialize diagnostic products generally, which could result in an inability to execute its plan of operations, the highly competitive environment in which Volition will be competing and resulting rapid product obsolescence, downturns in domestic and foreign economies, and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

📄 View original content:<http://www.prnewswire.com/news-releases/volition-announces-cameron-reynolds-president-and-chief-executive-officer-invited-as-presenter-at-maxims-covid-19-virtual-conference-301065942.html>

SOURCE VolitionRx Ltd